PIOL
MCID: INT054
MIFTS: 48

Intraocular Lymphoma (PIOL)

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intraocular Lymphoma

MalaCards integrated aliases for Intraocular Lymphoma:

Name: Intraocular Lymphoma 12 74 29 54 44 15 37 71
Primary Intraocular Lymphoma 12 58
Primary Intraocular Non-Hodgkin Malignant Lymphoma 71
Primary Intraocular Non-Hodgkin Lymphoma 58
Piol 58

Characteristics:

Orphanet epidemiological data:

58
primary intraocular lymphoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare eye diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:775
MeSH 44 D064090
NCIt 50 C9184
ICD10 via Orphanet 33 C85.7
UMLS via Orphanet 72 C0281658
Orphanet 58 ORPHA279904
UMLS 71 C0281658 C1706527

Summaries for Intraocular Lymphoma

MalaCards based summary : Intraocular Lymphoma, also known as primary intraocular lymphoma, is related to primary central nervous system lymphoma and lymphoma, hodgkin, classic. An important gene associated with Intraocular Lymphoma is CXCR5 (C-X-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are PAK Pathway and Allograft rejection. The drugs Ketamine and Orange have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and liver, and related phenotypes are cellular and hematopoietic system

Wikipedia : 74 Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye... more...

Related Diseases for Intraocular Lymphoma

Diseases related to Intraocular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 30.7 PAX5 CXCR5 BCL6 BCL2
2 lymphoma, hodgkin, classic 30.4 PAX5 BCL6 BCL2
3 b-cell lymphoma 30.4 PAX5 CXCR5 CXCR4 BCL6 BCL2
4 lymphoma 30.2 PAX5 CXCR5 CXCR4 BCL6 BCL2
5 central nervous system lymphoma 29.9 PAX5 IL10 CXCR5 CXCR4 CXCL12 BCL6
6 b-cell non-hodgkin lymphoma 29.9 IL10 BCL6
7 cytomegalovirus retinitis 29.8 IL10 CXCL12
8 testicular lymphoma 29.8 IGHV4-38-2 BCL6
9 acquired immunodeficiency syndrome 29.7 IL10 CXCR5 BCL6
10 diffuse large b-cell lymphoma 29.7 PAX5 IL10 CXCR4 BCL6 BCL2
11 retina lymphoma 29.7 IL10 IGHV4-38-2 CXCR5
12 lymphoma, non-hodgkin, familial 29.3 PAX5 IGHV4-38-2 CXCR5 CXCR4 CXCL12 BCL6
13 marginal zone b-cell lymphoma 29.2 PAX5 IGHV4-38-2 BCL6 BCL2
14 lymphoma, mucosa-associated lymphoid type 29.0 PAX5 IGHV4-38-2 CXCR5 BCL6 BCL2
15 uveitis 10.6
16 pars planitis 10.3
17 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.3 CXCR5 BCL6
18 neuroretinitis 10.3
19 retinitis 10.3
20 paranasal sinus lymphoma 10.2 PAX5 BCL6
21 lung lymphoma 10.2 PAX5 BCL6
22 myopia 10.2
23 hodgkin's lymphoma, nodular sclerosis 10.2 PAX5 BCL6
24 gray zone lymphoma 10.2 PAX5 BCL6
25 panuveitis 10.2
26 aids dementia complex 10.2 CXCR4 CXCL12
27 primary cutaneous b-cell lymphoma 10.2 PAX5 BCL6
28 gallbladder lymphoma 10.2 PAX5 BCL6
29 mental retardation, autosomal dominant 40 10.2 CXCR4 CXCL12
30 macular retinal edema 10.1
31 nodal marginal zone b-cell lymphoma 10.1 BCL6 BCL2
32 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.1 BCL6 BCL2
33 chest wall lymphoma 10.1 IGHV4-38-2 BCL6
34 follicular lymphoma 1 10.1 BCL6 BCL2
35 intravascular large b-cell lymphoma 10.1 BCL6 BCL2
36 monoclonal paraproteinemia 10.1 PAX5 IGHV4-38-2
37 nasal cavity lymphoma 10.1 IGHV4-38-2 BCL6
38 cataract 10.1
39 pediatric lymphoma 10.1 IGHV4-38-2 BCL6
40 spherocytosis, type 5 10.1 CXCR4 CXCL12
41 lymphosarcoma 10.1 BCL6 BCL2
42 human herpesvirus 8 10.1 BCL6 BCL2
43 b-lymphoblastic leukemia/lymphoma 10.1 PAX5 CXCR5 CXCR4
44 mental retardation, autosomal dominant 33 10.0 PAX5 IGHV4-38-2
45 retinal detachment 10.0
46 sarcoidosis 1 10.0
47 choroiditis 10.0
48 retinal vasculitis 10.0
49 posterior uveitis 10.0
50 keratopathy 10.0

Graphical network of the top 20 diseases related to Intraocular Lymphoma:



Diseases related to Intraocular Lymphoma

Symptoms & Phenotypes for Intraocular Lymphoma

MGI Mouse Phenotypes related to Intraocular Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.92 BCL2 BCL6 CXCL12 CXCR4 CXCR5 FOLR1
2 hematopoietic system MP:0005397 9.86 ABCC1 BCL2 BCL6 CXCL12 CXCR4 CXCR5
3 immune system MP:0005387 9.76 ABCC1 BCL2 BCL6 CXCL12 CXCR4 CXCR5
4 muscle MP:0005369 9.43 BCL2 BCL6 CXCL12 CXCR4 IL10 PAX5
5 neoplasm MP:0002006 9.02 BCL2 CXCR4 FOLR1 IL10 PAX5

Drugs & Therapeutics for Intraocular Lymphoma

Drugs for Intraocular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2 Orange Approved Phase 3
3
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
4
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
5
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
6
Ofloxacin Approved Phase 3 82419-36-1 4583
7
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
8
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
9
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
10
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
11
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
12
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
13
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Anesthetics, Dissociative Phase 3
16 Cytochrome P-450 Enzyme Inhibitors Phase 3
17 Antifungal Agents Phase 3
18 Amebicides Phase 3
19 Liposomal amphotericin B Phase 3
20 Antilymphocyte Serum Phase 2, Phase 3
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
22
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
24
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
25
Voriconazole Approved Phase 2 137234-62-9 71616
26
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
27 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
28
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
31
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
32
Gemcitabine Approved Phase 2 95058-81-4 60750
33
alemtuzumab Approved, Investigational Phase 2 216503-57-0
34
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
35
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
36
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
37
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
38
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
39
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
40
Lenograstim Approved, Investigational Phase 2 135968-09-1
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
42
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
43
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
44
Oblimersen Experimental, Investigational Phase 2 190977-41-4
45
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
46 Gastrointestinal Agents Phase 2
47 Antiemetics Phase 2
48 Cytochrome P-450 CYP3A Inhibitors Phase 2
49 Neuroprotective Agents Phase 2
50 Cyclosporins Phase 2

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
4 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
5 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
6 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
7 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
8 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
9 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
12 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
16 Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
17 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
18 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
19 Primary Central Nervous System Non-Hodgkins's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older) Completed NCT00003278 Phase 2 dexamethasone
20 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
21 Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
22 BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
23 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
24 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
25 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
26 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
27 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
28 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
29 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
30 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
31 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
32 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
33 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
34 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
35 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
36 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
37 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
38 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
39 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
40 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
41 Combined Intravitreal Methotrexate and R2 Regimen Followed by Lenalidomide Maintenance in Newly-diagnosed Primary Vitreoretinal Lymphoma Recruiting NCT03746223 Phase 2 Methotrexate;Rituximab;Lenalidomide
42 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
43 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
44 Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma Active, not recruiting NCT02542514 Phase 2 Ibrutinib
45 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
46 A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen Terminated NCT00074165 Phase 2 Rituxan;Cyclophosphamide;Etoposide;Etoposide phosphate;Carboplatin;Sodium thiosulfate;Neupogen;Neulasta;Cytarabine
47 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
48 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
49 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
50 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2

Search NIH Clinical Center for Intraocular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intraocular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Intraocular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Intraocular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: intraocular lymphoma

Genetic Tests for Intraocular Lymphoma

Genetic tests related to Intraocular Lymphoma:

# Genetic test Affiliating Genes
1 Intraocular Lymphoma 29

Anatomical Context for Intraocular Lymphoma

MalaCards organs/tissues related to Intraocular Lymphoma:

40
Eye, Retina, Liver, Bone Marrow, Bone, Endothelial, Monocytes

Publications for Intraocular Lymphoma

Articles related to Intraocular Lymphoma:

(show top 50) (show all 435)
# Title Authors PMID Year
1
Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. 61 54
19484437 2009
2
IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. 61 54
17591896 2007
3
[Diagnostic value of interleukin-10 and interleukin-6 in the vitreous of intraocular malignant lymphoma patients]. 61 54
15242071 2004
4
Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. 54 61
12578791 2003
5
Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. 54 61
10476821 1999
6
Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogeneous IgH gene rearrangement. 54 61
10496399 1999
7
Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. 54 61
9298057 1997
8
Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. 54 61
7485372 1995
9
Prevalence and causes of clinically detectable uveitic serous retinal detachment. 61
33530714 2021
10
Review of de novo uveitis in older adults presenting to a large tertiary centre. 61
33597198 2021
11
Clinical features of uveitis in elderly patients in central Tokyo (2013-2018). 61
33544350 2021
12
Intraocular T-cell lymphoma metastasizing from a primary adrenal T-cell lymphoma: Case report. 61
33304580 2020
13
The diagnostic value of IL-10 and IL-6 level in vitreous fluid and aqueous humor for vitreoretinal lymphoma. 61
33387464 2020
14
IgG4-related ophthalmic disease mimicking intraocular lymphoma: a case report. 61
33181803 2020
15
Granulomatous panuveitis associated with Hodgkin lymphoma: A case report with review of the literature. 61
33153312 2020
16
MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker. 61
32971631 2020
17
Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma. 61
33087316 2020
18
Discrimination of dissociated lymphoma cells from leukocytes by Raman spectroscopy. 61
32978443 2020
19
Multidisciplinary Diagnostic Approach in Intraocular Lymphoma Featuring Pseudo-hypopyon: Case Series and Literature Review. 61
32965144 2020
20
[Diagnostics and grading of intraocular lymphoma]. 61
32945914 2020
21
[Intraocular lymphoma as differential diagnosis of peripheral choroidal neovascularization]. 61
32945915 2020
22
Obtaining undiluted vitreous sample using small gauge pars plana vitrectomy and air infusion. 61
32637728 2020
23
Neuro-Ophthalmic Manifestations of Intracranial Malignancies. 61
32282510 2020
24
Logistic Regression Classification of Primary Vitreoretinal Lymphoma versus Uveitis by Interleukin 6 and Interleukin 10 Levels. 61
32197914 2020
25
Unmasking of infectious retinitis and intraocular lymphoma in patients after uneventful dropless cataract surgery. 61
32773549 2020
26
Choroidal neovascularization as a complication of primary vitreous retinal lymphoma. 61
32551977 2020
27
[Resection of a submacular traction membrane due to significant visual impairment : Case report]. 61
32504126 2020
28
Unmasking of infectious retinitis and intraocular lymphoma in patients following uncomplicated dropless cataract surgery. 61
32618832 2020
29
Rituximab-Associated Retinal Occlusive Vasculopathy: A Case Report and Literature Review. 61
31314626 2020
30
Primary intraocular lymphoma. 61
31899059 2020
31
Presumed Intraocular Lymphoma Masquerading as Age-Related Macular Degeneration: A Case Report. 61
32671308 2020
32
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31972811 2020
33
Analysis of inflammatory mediators in the vitreous humor of eyes with pan-uveitis according to aetiological classification. 61
32066796 2020
34
Changes in Etiology of Uveitis in a Single Center in Japan. 61
32068467 2020
35
Usefulness of Combined Measurement of Serum Soluble IL-2R and Angiotensin-Converting Enzyme in the Detection of Uveitis Associated with Japanese Sarcoidosis. 61
32848359 2020
36
Clinical and histopathological classification of feline intraocular lymphoma. 61
31328872 2020
37
THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. 61
29210961 2020
38
Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas? 61
31611509 2019
39
Cornea Findings of Spectral Domain Anterior Segment Optical Coherence Tomography in Uveitic Eyes of Various Etiologies. 61
31335529 2019
40
Clinical and etiologic characteristics of de novo uveitis in patients aged 60 years and above: experience of a French tertiary center. 61
31312906 2019
41
Epidemiology and clinical features of intraocular lymphoma in Singapore. 61
32792692 2019
42
Pomalidomide in primary intraocular lymphoma. 61
30632826 2019
43
[Diagnostic vitrectomy in intraocular inflammations: A retrospective series]. 61
31084938 2019
44
Diagnostic dilemma of ocular lymphoma. 61
31175115 2019
45
Primary Choroidal Lymphoma Diagnosed with 27-Gauge Pars Plana Vitrectomy Choroidal Biopsy. 61
31692619 2019
46
CLINICAL PATHOLOGIC CORRELATION OF SARCOIDOSIS-ASSOCIATED MULTIFOCAL CHORIORETINITIS IN AN ELDERLY PATIENT. 61
28145942 2019
47
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. 61
30698644 2019
48
Flow cytometry immunophenotyping of vitreous specimens does not contribute to diagnosis of lymphoma without supporting morphologic features. 61
30485724 2019
49
Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma. 61
30489610 2019
50
Primary vitreoretinal lymphoma: prevalence, impact, and management challenges. 61
30858685 2019

Variations for Intraocular Lymphoma

Expression for Intraocular Lymphoma

Search GEO for disease gene expression data for Intraocular Lymphoma.

Pathways for Intraocular Lymphoma

Pathways related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 IL10 CXCR5 CXCR4 CXCL12 BCL2
2
Show member pathways
12.48 IL10 CXCR5 CXCR4 CXCL12
3
Show member pathways
11.96 IL10 CXCR4 CXCL12 BCL2
4
Show member pathways
11.79 IL10 CXCR5 CXCR4 CXCL12
5 11.61 PAX5 IL10 CXCR5 CXCR4 CXCL12 BCL6
6 11.6 IL10 BCL6 BCL2
7
Show member pathways
11.09 IL10 BCL2
8 11.08 PAX5 IL10 CXCR5 BCL6
9 11.02 CXCR4 CXCL12
10 11 FOLR1 ABCC1
11 10.89 IL10 BCL2
12 10.82 BCL2 ABCC1
13
Show member pathways
10.71 FOLR1 ABCC1
14 10.32 BCL2 ABCC1

GO Terms for Intraocular Lymphoma

Cellular components related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 IGHV4-38-2 CXCR5 CXCR4 CXCL12

Biological processes related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.83 IL10 CXCR5 CXCR4 CXCL12
2 chemotaxis GO:0006935 9.69 CXCR5 CXCR4 CXCL12
3 B cell differentiation GO:0030183 9.58 IL10 BCL6 BCL2
4 positive regulation of B cell proliferation GO:0030890 9.57 BCL6 BCL2
5 negative regulation of mitotic cell cycle GO:0045930 9.56 IL10 BCL2
6 B cell proliferation GO:0042100 9.55 IL10 BCL2
7 response to radiation GO:0009314 9.54 CXCL12 BCL2
8 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.49 CXCR4 CXCL12
9 axon regeneration GO:0031103 9.48 FOLR1 BCL2
10 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.46 CXCR4 CXCL12
11 leukocyte chemotaxis GO:0030595 9.43 IL10 CXCR5
12 telencephalon cell migration GO:0022029 9.37 CXCR4 CXCL12
13 regulation of programmed cell death GO:0043067 9.32 CXCR4 BCL2
14 type 2 immune response GO:0042092 9.26 IL10 BCL6
15 response to ultrasound GO:1990478 9.16 CXCR4 CXCL12
16 regulation of calcium ion transport GO:0051924 9.13 CXCR4 CXCL12 BCL2
17 cell chemotaxis GO:0060326 8.92 CXCR5 CXCR4 CXCL12 ABCC1

Molecular functions related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-C chemokine binding GO:0019957 9.16 CXCR5 CXCR4
2 C-C chemokine receptor activity GO:0016493 8.96 CXCR5 CXCR4
3 C-X-C chemokine receptor activity GO:0016494 8.62 CXCR5 CXCR4

Sources for Intraocular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....